ZONA Zonagen (MM)

Zonagen, Inc. (NasdaqSC: ZONA) will present at the following forum: What: Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum When: June 15, 2005 @ 2:35 PM Eastern Time Sponsors: Barron's, The Wall Street Journal, The American Stock Exchange and Business Wire Keynote Presentations: Lynn Sutherland, M.S., M.B.A. - President, Sutherland Consulting Dr. Navdeep Jaikaria, Senior Biotechnology Analyst, Rodman & Renshaw, LLC Where: The Princeton Club of New York, 15 West 43rd Street., New York City, NY 10036 How to attend: Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.informedinvestors.com/CustomEvent/89559/index.asp If you are unable to attend the live event, the forum will be available via webcast at http://www.informedinvestors.com/CustomEvent/89559/index.asp Contact: Louis Ploth, Jr., lploth@zonagen.com , 281-719-3454 Zonagen is a clinical-stage biopharmaceutical company focused on the development of new, orally administered, small molecule drugs to treat hormonal and reproductive system disorders. The Company's two main products are Progenta(TM) for the treatment of adverse symptoms associated with uterine fibroids and endometriosis and Androxal(TM) for the treatment of testosterone deficiency. The Company intends to begin a U.S. Phase III clinical trial for Androxal by year end 2005. The Company believes it has sufficient data from its completed Phase lb trial for the treatment of uterine fibroids to adequately select dose for an advanced U.S. Phase II trial which is anticipated to begin by year end 2005. The Company hopes that this Phase II trial may meet the requirements to be the first pivotal trial of two required pivotal trials. In addition, the Company intends to initiate a European Phase II trial for the treatment of endometriosis by year end 2005. Senior management of the Company has extensive experience in product clinical development through the NDA process as well as experience securing partnerships with major pharmaceutical companies. In order to keep the burn rate to a minimum, the Company operates as a near-virtual company, outsourcing the majority of tasks associated with their development programs, including all preclinical and clinical research and development. www.zonagen.com